Femasys Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $17.1M
- Price
- $2.04
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.25%
- Volume
- 67.7K
About
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Quick stats
Shares outstanding8.4M
Computed float7.3M
Float / shares87.3%
Cash runway (months)20.1
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001339005
Websitehttps://www.femasys.com
AI Summary
AI-generated1/16
minorbullishoperations update
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
Femasys Inc. said Minnesota Women's Care will implement FemVue for fertility diagnostic evaluation and FemaSeed Complete for in-office first-line fertility treatment across all four of its OB/GYN practice locations.
Femasys CEO Kathy Lee-Sepsick said the multi-site adoption reflects early recognition of the fertility portfolio's value and that, following the company's August financing, Femasys is expanding its commercial team to support broader OB/GYN adoption.
No financial terms were disclosed; the win signals early commercial traction for the FemaSeed portfolio while the lead pipeline asset FemBloc remains in the FINALE pivotal trial ahead of a targeted U.S. FDA approval.
Red flags
- No contract value, revenue contribution, or adoption timeline disclosed
- Commercial push follows an unquantified August financing — dilution context for a micro-cap